Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.
NCT ID: NCT06342544
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
128 participants
INTERVENTIONAL
2025-04-29
2029-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In the initial phase of the disease, 70% of patients present with ocular onset myasthenia (OMG), i.e. weakness limited to the oculomotor muscles. Generalization to skeletal, bulbar and axial muscles occurs in 20-40% of cases, with a higher frequency in the first and second years, respectively 46% and 60% of generalizations. This reflects the maturation of the autoimmune response in the early years of the disease, and represents a therapeutic window of opportunity to modify the course of the disease.
Generalization is a critical event, putting the patient at risk of admission to an intensive care unit and necessitating the use of long-term immunosuppressants.
There is currently no validated strategy for preventing generalization. On the one hand, a preventive role for corticosteroid therapy in ocular-onset myasthenia has been observed in some studies, but not confirmed by others. These contradictory results may be explained by the bias of retrospective observational studies and the use of different corticosteroid administration regimens.
On the other hand, recent data on the use of low-dose Rituximab in the early phase of the disease shows greater efficacy than later use, enabling prolonged remission of the disease with a very good tolerability profile.
We propose to compare in a randomized controlled trial the usual practice with a proactive strategy with a standardized corticosteroid regimen immediate at diagnosis.
Patients with ocular myasthenia are usually treated symptomatically with acetylcholinesterase inhibitors. The introduction of corticosteroids is delayed and limited to patients with persistent disabling diplopia or ptosis with occlusion. When corticosteroids are tapered off, ocular symptoms may recur. This level of corticosteroid dependence observed in patients treated for ocular myasthenia has not been specifically studied. In order to reduce the levels of corticosteroids administered and avoid recurrence of ocular symptoms and their delayed generalization, it is usually proposed to introduce another immunosuppressant.
The aim of this study is to evaluate the efficacy of a standardized proactive prevention strategy on the generalization of ocular onset myasthenias during the first 2 years. It will combine immediate treatment with corticosteroids at the time of diagnosis, with the addition of rituximab in the event of recurrence of ocular symptoms as corticosteroids are tapered off.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
NCT05868837
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
NCT04182984
OVEMP in Myasthenia
NCT03049956
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
NCT03863080
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
NCT00727194
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
immediate treatment with corticosteroids addition of rituximab if recurrence
immediate treatment with corticosteroids
Immediate standardized treatment with corticosteroids. Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.
addition of rituximab if recurrence
rituximab added if ocular symptoms reappear as corticosteroids are tapered off. Rituximab will be given at a dose of 500mg/6months for 12 months.
based on standard practice
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
immediate treatment with corticosteroids
Immediate standardized treatment with corticosteroids. Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.
addition of rituximab if recurrence
rituximab added if ocular symptoms reappear as corticosteroids are tapered off. Rituximab will be given at a dose of 500mg/6months for 12 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of ocular myasthenia within the last 6 months, defined :
* either by a typical clinical examination objectified by an expert clinician: ptosis and/or binocular diplopia, with a variable and fluctuating character (either spontaneous or provoked by effort or rest)
* or by positive anti-AChR antibodies or the presence of decrement on repetitive nerve stimulation or a positive edrophonium test
* Ocular symptoms lasting at least one month and limited to extra-ocular muscles (weakness in one or both orbicularis oculi)
* No non-ocular symptoms on MMS, MGC and MG-ADL.
* Naïve to immunosuppressive therapy for ocular myasthenia gravis.
Exclusion Criteria
* Pupillary anomaly other than that resulting from previous local disease or surgery.
* Signs of restrictive abduction or supraduction myopathy due to dysthyroid ophthalmopathy.
* Graves' ophthalmopathy
* Onset of ocular symptoms more than one year before screening date
* Hypersensitivity to rituximab, murine proteins, prednisone, methylprednisone, aziathioprine or 6-mercaptopurine, paracetamol, dexchlorpheniramine.
* Any infectious condition
* Patients with severe immune deficiency
* Severe heart failure (New York Heart Association (NYHA) Class IV) or severe uncontrolled heart disease
* Severe hepatic insufficiency
* Psychotic states not yet controlled by treatment
* Hyperuricemia on xanthine oxidase inhibitors (allopurinol and febuxostat)
* Risk of angle-closure glaucoma
* Risk of urinary retention due to urethro-prostatic disorders
* Vaccination with live attenuated vaccine required during study and up to 6 months after rituximab discontinuation
* Women of childbearing age who do not wish to use effective contraception during their participation and at least 12 months after
* Pregnant or breast-feeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire De Bordeaux
Bordeaux, , France
Hôpital Raymond Pointcarre
Garches, , France
Centre Hospitalier Universitaire De Lille
Lille, , France
Hospices Civils De Lyon
Lyon, , France
Centre Hospitalier Universitaire De Nice
Nice, , France
CHNO
Paris, , France
Hôpital de la Pitié-Salpêtrière
Paris, , France
Centre Hospitalier Sainte Anne
Paris, , France
Fondation Adolphe de Rothschild
Paris, , France
Les Hopitaux Universitaires De Strasbourg
Strasbourg, , France
Centre Hospitalier Universitaire De Toulouse
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AGN_2023_14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.